MedicaidPrior AuthLow impact
Emrelis (telisotuzumab vedotin-tllv) (Revised)
Humana·IN · Oncology, Pulmonology·Medicaid
Effective date
Sep 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid (Indiana) has established a new prior authorization policy for Emrelis (telisotuzumab vedotin-tllv), a cancer drug for treating advanced non-small cell lung cancer. Prior authorization is required for all Emrelis prescriptions starting September 1, 2025, with specific criteria including high c-Met protein overexpression and previous systemic therapy.
Action Required
By September 1, 2025: Billing and clinical teams must implement prior authorization requirements for Emrelis (telisotuzumab vedotin-tllv) prescriptions for Indiana Medicaid patients. Providers must verify patients meet all four criteria: locally advanced/metastatic non-squamous EGFR wild-type NSCLC, high c-Met protein overexpression (≥50% IHC 3+), previous systemic therapy, and monotherapy use. Update EMR templates to document required clinical criteria and ensure prior authorization is obtained before prescribing. Claims will be denied without proper authorization.